gainbot
BriefMoversScreensSectorsEarningsIPOsNewsDividends & splitsScreenerWatchlistLearn
NASDAQ · STROHealthcareBiotechnology

Sutro Biopharma, Inc. (STRO)

$9.60+0.95%
Close Nov 4, 2026 · split-adjusted
Nov 4, 2026$9.60▼ 12.73% in range
Nov 3, 2025Low $7.30 · High $40.91Nov 4, 2026
What changed · written from our data
As of Nov 4, 2026

Sutro Biopharma closed at $9.60 on Nov 4, up 0.95%, 76.5% below its 52-week closing high. Volume of 68.4K shares was 0.20× its 20-day average (below normal).

Split-adjusted performance: -33.6% over one month, -74.5% over six months, -12.7% over one year.

In the quarter ended Jun 30, 2026, revenue was $9.84M, down 84.6% from a year earlier, with a net margin of -391.6%.

Short interest was 2.0M shares at the Oct 15 settlement, up 6.1% from the prior report (13.1% of float, 6.3 days to cover).

Market cap$159.2M16.6M shares
Revenue · quarter$9.8M−84.6% YoY
Diluted EPS$-2.33—
P/E · TTM—P/S 3.5×
Net margin-391.6%Gross 100.0%
Dividend yieldNone
52-week range7.30 – 40.91−76.5% from high
Volume68.4K0.20× 20-day avg
Volatility · 60d74.5%Annualised
Short % of float13.1%6.3 days to cover
Net cash$164.3MCash $164.3M
Next earnings—Not scheduled
Split-adjusted performance
1W +3.3%1M −33.6%3M −60.2%6M −74.5%YTD −17.0%1Y −12.7%3Y −62.8%5Y −95.1%

Earnings reactions

History →

No reported quarters with price history yet.

Rank within Biotechnology

Percentile among 139 companies (100 = best)

6-month momentum9
Revenue growth13
Net margin45
Value (low P/E)—
Size42

Industry medians: 6-month return −19.5%, revenue growth +8.8%, net margin −312.9%, P/E 22.2×.

Short interest

Details →
Shares short2.0M+6.1% vs prior
Days to cover6.3Settled Oct 15
% of float13.1%
Short vol. 10d51.7%of daily volume

Closest peers by size in Biotechnology

CompanyPriceToday6MRev. growthNet marginP/EMkt cap
STROSutro Biopharma$9.60+0.95%−74.5%−84.6%−391.6%—$159.2M
TARAProtara Therapeutics$2.40−0.41%−57.6%———$141.8MCompare
CMPXCompass Therapeutics$0.7720+2.52%−58.7%———$139.0MCompare
ACOGAlpha Cognition$8.40+2.44%+31.7%+267.6%−144.3%—$182.9MCompare
IVVDInvivyd$0.6334+8.93%−56.6%+21.2%−310.8%—$186.7MCompare
CHRSCoherus Oncology$0.8573+6.42%−51.0%+39.5%−144.2%—$132.5MCompare
HUMAHumacyte$0.4465+1.36%−54.6%+34.9%−9064.5%—$124.0MCompare
ARTVArtiva Biotherapeutics$4.19−0.36%−66.2%———$204.6MCompare
ARMPArmata Pharmaceuticals$3.20+3.56%−64.7%+15.7%2953.8%—$119.0MCompare

News about Sutro Biopharma

All news →
Sutro Biopharma to Participate in Upcoming Investor ConferencesGlobeNewswire Inc. · 19h agoNeutralSutro Biopharma Presents Promising Preclinical Data Across its Pipeline of Next-Generation Single and Dual-Payload ADC Programs at AACR 2026GlobeNewswire Inc. · Apr 19, 2026▲ PositiveSutro Biopharma Announces Pricing of $110.0 million Underwritten OfferingGlobeNewswire Inc. · Feb 10, 2026▲ Positive

Quick answers

What does Sutro Biopharma do?
Sutro Biopharma Inc is a clinical-stage drug discovery, development, and manufacturing company. The company manufactures next-generation protein therapeutics for cancer and autoimmune disorders through its proprietary integrated cell-free protein synthesis platform, XpressCF.
What is STRO's market cap?
$159.18M, based on the Nov 4 close of $9.60.
Does Sutro Biopharma pay a dividend?
No regular cash dividend has been paid in the last year.
How much of STRO is sold short?
2.0M shares, 13.1% of float, as of Oct 15, 2026.
What sector is STRO in?
Healthcare, in the Biotechnology industry.

About Sutro Biopharma

Sutro Biopharma Inc is a clinical-stage drug discovery, development, and manufacturing company. The company manufactures next-generation protein therapeutics for cancer and autoimmune disorders through its proprietary integrated cell-free protein synthesis platform, XpressCF. Products offered by the company include STRO-001 for patients with multiple myeloma and lymphoma and STRO-002 for the treatment of ovarian and endometrial cancers. Company's wholly-owned product candidate is STRO-004, a single homogeneous ADC directed against tissue factor which are developing for the treatment of solid tumors. The company also pipeline contains STRO-006, STRO-00X, STRO-00Y, STRO-003, VAX24, VAX31, and Others.

HQ: South San Francisco, CA128 employeesListed Sep 27, 2018sutrobio.com

Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology